Latigo Biotherapeutics Raises $135M in Series A

Latigo Biotherapeutics, a Thousand Oaks, CA-based clinical-stage biotechnology company developing non-opioid pain medicines that target pain at its source, raised $135M in Series A funding.

Westlake Village BioPartners incubated the company and led the round with 5AM Ventures and Foresite Capital as co-leads with participation from Corner Ventures. The company has appointed Desmond Padhi, Pharm.D., operating partner at Westlake as interim chief executive officer (CEO) and Nancy Stagliano, Ph.D., CEO of Neuron23, Inc., as chair of the board.

The company intends to use the funds to support the continued advancement of its portfolio of novel pain therapeutics.

Led by CEO Desmond Padhi, Latigo Biotherapeutics is a clinical-stage biotechnology company developing non-opioid pain medicines that target the fundamental mechanism of pain transduction. Its proprietary, in-house technology generates novel drugs against targets validated by human genetics using the most advanced artificial intelligence, machine learning, structure-based, and knowledge-based design techniques to optimize potency and selectivity.

Latigo’s lead program, LTG-001, is an oral, selective Nav1.8 inhibitor currently in a Phase 1 clinical trial in healthy volunteers and intended to treat acute and chronic pain. LTG-001 has the potential to be best-in-class with a rapid onset, meaningful efficacy, and superior safety to standard of care with no central nervous system effects. In addition to LTG-001, the company has a suite of Nav1.8 inhibitors, enabling Latigo to address the broad potential of such a target in the clinic. Beyond Nav1.8, the company has a pipeline of novel, genetically identified targets with small molecule programs at the discovery stage.